Lyrfigtu (lirafugratinib) is an oral kinase inhibitor indicated for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Lirafugratinib targets fibroblast growth factor receptor signaling, a pathway that can contribute to tumor growth and progression in cancers driven by FGFR2 alterations. Lyrfigtu provides a biomarker-driven treatment option for patients with FGFR2 fusion- or rearrangement-positive cholangiocarcinoma following prior systemic therapy.
Its targeted mechanism allows treatment to be guided by the molecular characteristics of the tumor, supporting a precision oncology approach in advanced bile duct cancer. The approval expands targeted treatment options for patients with this genetically defined form of cholangiocarcinoma.
